• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌患者就诊时 CA125 的术前水平相关因素。

Correlates of the preoperative level of CA125 at presentation of ovarian cancer.

机构信息

Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Gynecol Oncol. 2010 Dec;119(3):462-8. doi: 10.1016/j.ygyno.2010.08.028. Epub 2010 Sep 17.

DOI:10.1016/j.ygyno.2010.08.028
PMID:20850174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2980911/
Abstract

OBJECTIVE

CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels. We examined the effect of epidemiologic variables and tumor features on CA125 at diagnosis and their effects on survival.

METHODS

CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded. CA125 values were log-normalized and generalized linear, logistic, or Cox proportional hazards models used to identify predictors of CA125 and influence on survival in the subset of women with invasive, nonmucinous tumors.

RESULTS

The importance of histology, grade, stage, laterality, and presence of ascites on CA125 level was confirmed. For nonmucinous invasive cancers, Jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher CA125, and greater body mass index (BMI), recurrent yeast infections, colitis, and appendectomy predicted lower CA125. A quadratic model best described the relationship between CA125 and age with lower levels in youngest and oldest women. In multivariate modeling, stage, ascites, and prior breast cancer were the strongest predictors of high CA125 and appendectomy and yeast infections strongest predictors of low CA125. A model with these variables plus CA125 revealed high CA125 remains a predictor of poorer survival.

CONCLUSIONS

Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.

摘要

目的

卵巢癌患者就诊时的 CA125 具有重要的预后意义;但除了肿瘤特征外,人们对影响 CA125 水平的因素知之甚少。我们研究了流行病学变量和肿瘤特征对诊断时 CA125 水平的影响及其对生存的影响。

方法

记录了在 Partners 医院接受治疗的 805 名卵巢癌女性的 CA125 水平、肿瘤特征和问卷调查数据。CA125 值进行对数正态化,然后使用广义线性、逻辑或 Cox 比例风险模型来确定影响非黏液性浸润性肿瘤患者 CA125 水平的预测因子及其对生存的影响。

结果

证实了组织学、分级、分期、侧别和腹水对 CA125 水平的重要性。对于非黏液性浸润性癌,犹太种族、产次、既往乳腺癌以及乳腺癌或卵巢癌家族史预测 CA125 水平更高,而较高的体重指数(BMI)、复发性酵母感染、结肠炎和阑尾切除术预测 CA125 水平更低。二次模型最好地描述了 CA125 与年龄之间的关系,最年轻和最年长的女性 CA125 水平较低。在多变量建模中,分期、腹水和既往乳腺癌是 CA125 水平升高的最强预测因子,阑尾切除术和酵母感染是 CA125 水平降低的最强预测因子。包含这些变量和 CA125 的模型表明,CA125 水平升高仍然是生存较差的预测因子。

结论

卵巢肿瘤特征和腹水的存在是诊断时 CA125 的关键决定因素,但 BMI、产次、既往乳腺癌以及生殖泌尿系统或胃肠道炎症性疾病的病史等流行病学特征也可能发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cf/2980911/d3f02a3a5757/nihms238531f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cf/2980911/d3f02a3a5757/nihms238531f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cf/2980911/d3f02a3a5757/nihms238531f1.jpg

相似文献

1
Correlates of the preoperative level of CA125 at presentation of ovarian cancer.卵巢癌患者就诊时 CA125 的术前水平相关因素。
Gynecol Oncol. 2010 Dec;119(3):462-8. doi: 10.1016/j.ygyno.2010.08.028. Epub 2010 Sep 17.
2
Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.中性粒细胞与淋巴细胞比值在卵巢癌中的预后意义及预测因素。
Gynecol Oncol. 2014 Mar;132(3):542-50. doi: 10.1016/j.ygyno.2014.01.026. Epub 2014 Jan 23.
3
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.卵巢癌诊断时预处理CA125的预测因素:卵巢癌协会联盟的汇总分析
Cancer Causes Control. 2017 May;28(5):459-468. doi: 10.1007/s10552-016-0841-3. Epub 2017 Jan 3.
4
Impact of body mass index on ovarian cancer survival varies by stage.体重指数对卵巢癌生存率的影响因分期而异。
Br J Cancer. 2017 Jul 11;117(2):282-289. doi: 10.1038/bjc.2017.162. Epub 2017 Jun 6.
5
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.识别上皮性卵巢癌高危绝经后女性。
Gynecol Oncol. 2015 Nov;139(2):253-60. doi: 10.1016/j.ygyno.2015.08.024. Epub 2015 Sep 3.
6
Differential blood count as triage tool in evaluation of pelvic masses.鉴别血球计数作为评估骨盆腔肿块的分诊工具。
Int J Gynecol Cancer. 2021 May;31(5):733-743. doi: 10.1136/ijgc-2019-001103. Epub 2020 Jun 2.
7
Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?交界性卵巢肿瘤患者术前CA125或CA19-9升高:这是否提示晚期或预后不良?
Gynecol Obstet Invest. 2018;83(1):45-51. doi: 10.1159/000475817. Epub 2017 Jun 2.
8
The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma.腹水、肿块大小及腹膜种植转移对卵巢癌患者血清CA125水平的影响。
Int J Gynecol Cancer. 2002 Sep-Oct;12(5):438-42. doi: 10.1046/j.1525-1438.2002.01171.x.
9
High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.高水平的预处理CA125与高级别浆液性卵巢癌患者生存率的提高相关。
J Ovarian Res. 2016 Jul 7;9(1):41. doi: 10.1186/s13048-016-0247-6.
10
Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.产褥期乳腺炎:一种重要的生殖事件,影响粘蛋白抗体水平和卵巢癌风险。
Cancer Causes Control. 2013 Nov;24(11):1911-23. doi: 10.1007/s10552-013-0266-1. Epub 2013 Aug 8.

引用本文的文献

1
Performance of the IOTA ADNEX model combined with HE4 for identifying early-stage ovarian cancer.IOTA ADNEX模型联合HE4用于识别早期卵巢癌的性能。
Front Oncol. 2022 Sep 16;12:949766. doi: 10.3389/fonc.2022.949766. eCollection 2022.
2
Management of the Adnexal Mass: Considerations for the Family Medicine Physician.附件肿物的管理:家庭医学医生的考量因素
Front Med (Lausanne). 2022 Jul 5;9:913549. doi: 10.3389/fmed.2022.913549. eCollection 2022.
3
A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers.

本文引用的文献

1
CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.卵巢癌患者中 CA125 浓度低时的 CA125 免疫复合物。
Clin Chem. 2010 Dec;56(12):1889-92. doi: 10.1373/clinchem.2010.153122. Epub 2010 Oct 13.
2
Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.123 例交界性卵巢肿瘤患者术前 CA-125 水平:回顾性分析及文献复习。
Int J Gynecol Cancer. 2009 Nov;19(8):1335-8. doi: 10.1111/IGC.0b013e3181a83e04.
3
Cancer antigen 125 levels in inflammatory bowel diseases.
一种用于改善上皮性卵巢癌早期检测的转化模型。
Front Oncol. 2022 Apr 21;12:786154. doi: 10.3389/fonc.2022.786154. eCollection 2022.
4
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.当CA125检测结果无诊断价值时对早期卵巢恶性肿瘤的挽救性检测
Diagnostics (Basel). 2021 Aug 10;11(8):1440. doi: 10.3390/diagnostics11081440.
5
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.欧洲妇科肿瘤学会(ESGO)/国际妇产科超声学会(ISUOG)/国际妇产科联盟肿瘤学组(IOTA)/欧洲妇科内镜学会(ESGE)关于卵巢肿瘤术前诊断的共识声明。
Int J Gynecol Cancer. 2021 Jul;31(7):961-982. doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10.
6
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours.ESGO/ISUOG/IOTA/ESGE关于卵巢肿瘤术前诊断的共识声明。
Facts Views Vis Obgyn. 2021 Jun;13(2):107-130. doi: 10.52054/FVVO.13.2.016. Epub 2021 Jun 10.
7
Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).血清 HE4 和 CA125 与国家健康和营养调查(NHANES)中女性的流行病学和生物学相关性。
Gynecol Oncol. 2021 Apr;161(1):282-290. doi: 10.1016/j.ygyno.2021.01.011. Epub 2021 Jan 24.
8
Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women.多变量指标检测在非裔美国女性卵巢恶性肿瘤检测中优于CA125和HE4检测。
Biomark Cancer. 2019 Jun 14;11:1179299X19853785. doi: 10.1177/1179299X19853785. eCollection 2019.
9
Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.[18F]氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描([18F]FDG-PET/CT)以及CA125血清水平和动力学参数在卵巢癌复发早期检测中的价值:组织学亚型和肿瘤分期的影响
Medicine (Baltimore). 2018 Apr;97(17):e0098. doi: 10.1097/MD.0000000000010098.
10
Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer.血清 miRNA 神经网络在卵巢癌检测中的诊断潜力。
Elife. 2017 Oct 31;6:e28932. doi: 10.7554/eLife.28932.
炎症性肠病中的癌抗原125水平。
J Clin Lab Anal. 2009;23(4):244-8. doi: 10.1002/jcla.20323.
4
The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.在前列腺、肺癌、结直肠癌和卵巢癌(PLCO)筛查试验中,无卵巢癌证据的女性CA-125的流行病学情况。
Gynecol Oncol. 2008 Sep;110(3):383-9. doi: 10.1016/j.ygyno.2008.05.006. Epub 2008 Jun 30.
5
MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence.MUC16在接受期人类子宫内膜的子宫圆顶(微绒毛)表面缺失:体外实验证据表明MUC16是滋养层细胞黏附的屏障。
Biol Reprod. 2008 Jan;78(1):134-42. doi: 10.1095/biolreprod.106.058347. Epub 2007 Oct 17.
6
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.血清CA-125与遗传性卵巢癌高风险女性的附件发育异常和癌症的关系。
J Clin Oncol. 2007 Apr 10;25(11):1383-9. doi: 10.1200/JCO.2006.06.7884.
7
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.持续性排卵、粘蛋白1免疫与卵巢癌风险
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):30-5. doi: 10.1158/1055-9965.EPI-06-0688.
8
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.卵巢肿瘤患者中CA125表达模式、预后及其与血清CA125的相关性。来自丹麦“MALOVA”卵巢癌研究。
Gynecol Oncol. 2007 Mar;104(3):508-15. doi: 10.1016/j.ygyno.2006.09.028. Epub 2006 Nov 17.
9
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.输卵管伞端是患有家族性卵巢癌综合征女性早期腺癌的好发部位。
Am J Surg Pathol. 2006 Feb;30(2):230-6. doi: 10.1097/01.pas.0000180854.28831.77.
10
CA125 and endometriosis.CA125与子宫内膜异位症。
Hum Reprod Update. 1995 Mar;1(2):173-87. doi: 10.1093/humupd/1.2.173.